Breakfast Technical Briefing: Sarepta Therapeutics, ACADIA Pharma, Cell
Therapeutics, and Medivation
LONDON, December 6, 2013
LONDON, December 6, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Thursday, December 05, 2013, the US equity market declined, as the S&P 500
ended the day at 1,785.03, down 0.43%; the Dow Jones Industrial Average closed
at 15,821.51, down 0.43%; and the NASDAQ Composite finished at 4,033.17, down
0.12%. TheS&P 500 Health Care Sector Index ended the day at 629.06, down
0.27%, while the S&P 500 Biotechnology Industry Index closed 0.59% higher at
2,750.26. Moreover, the S&P 500 Biotechnology Industry Index has gained 5.03%
in the previous one month and 11.86% in the last three months, outperforming
the S&P 500, which has gained 1.25% and 7.85% during the respective
periods.The major movers in the industry included Sarepta Therapeutics
Inc.(NASDAQ: SRPT),ACADIA Pharmaceuticals Inc.(NASDAQ: ACAD),Cell
Therapeutics Inc.(NASDAQ: CTIC), and Medivation Inc.(NASDAQ: MDVN).
AAAResearchReports.com free coverage on SRPT, ACAD, CTIC, and MDVN is
available upon registration at:
On Thursday, shares in Sarepta Therapeutics Inc. rose 1.50%, even as the
broader market finished on a negative note. The company's shares closed the
day at $18.98, after fluctuating between $18.70 and $19.26 during the trading
session. A total of 1.02 million shares were traded, which is below the daily
average volume of 2.97 million. The company's shares have advanced 3.43% in
the previous three trading sessions, compared to a loss of 0.88% in the S&P
500 during the same period. However, Sarepta Therapeutics Inc.'s stock is
trading below its 50-day and 200-day moving averages of $34.85 and $35.66,
respectively. Download free technical research on SRPT by signing up at:
Shares in ACADIA Pharmaceuticals Inc. gained 0.78% on Thursday, finishing the
day at $24.48 after oscillating between $24.00 and $25.77 during the trading
session. A total of 1.84 million shares were traded, which is below the daily
average volume of 2.58 million. ACADIA Pharmaceuticals Inc.'s shares have
gained 15.47% in the previous three months and 8.08% in the last one month,
outperforming the S&P 500, which has gained 7.85% and 1.25% during the
respective periods. Furthermore, the company's stock is trading above its
50-day and 200-day moving averages of $23.61 and $17.34, respectively.
Register now and get access to free analysis on ACAD at:
Cell Therapeutics Inc.'s stock declined 2.05% on Thursday, ending the day at
an intra-day low of $1.91, after vacillating between $1.91 and $1.97 during
the trading session. A total of 1.48 million shares were traded, which is
below the daily average volume of 3.34 million. Despite Thursday's losses, the
company's shares have surged 73.64% in the previous three months and 10.40% in
the last one month, outperforming the S&P 500, which has gained 7.85% and
1.25% during the respective periods. Moreover, Cell Therapeutics Inc.'s stock
is trading above its 50-day and 200-day moving averages of $1.81 and $1.33,
respectively. Sign up and read our complimentary report on CTIC at:
On Thursday, Medivation Inc.'s stock closed the day at $61.29, down 1.62% from
the previous day's closing price of $62.30. The company's shares vacillated
between $61.14 and $62.60 during the trading session. A total of 0.79 million
shares were traded, which is below the daily average volume of 1.31 million.
The company's shares have advanced 1.31% in the previous three months,
underperforming the S&P 500, which has gained 7.85% during the same period.
However, Medivation Inc.'s stock is trading above its 50-day and 200-day
moving averages of $59.37 and $54.10, respectively. The free report on MDVN
can be downloaded by signing up now at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: Phone #: + 1 (646) 396-9126 Contact Name: Peter F. Jones Email ID:
Press spacebar to pause and continue. Press esc to stop.